Moody’s Announces Leadership Succession
Moody’s Corporation (NYSE:MCO) announced today that Raymond McDaniel, Jr. will retire as President and Chief Executive Officer on December 31, 2020 after nearly 34 years of service to the company, including more than 15 years as CEO. Mr. McDaniel will remain on the Moody’s Board of Directors, where he will assume the role of non-executive Chairman, effective January 1, 2021.
The Board of Directors unanimously elected Robert Fauber, the current Chief Operating Officer (COO), as President and CEO of Moody’s, effective January 1, 2021. Mr. Fauber will also join the company’s Board, effective immediately.
Henry A. McKinnell, Jr., PhD, who has served as the Chairman of Moody’s since 2012, will remain on the Board as a Director.
“Moody’s has never been in a stronger position, and as the company continues its evolution as a trusted global provider of risk assessments, now is the right time for this transition to take place,” said Mr. McDaniel. “Rob’s impressive track record of achievements during his 15 years at Moody’s and deep understanding of our core businesses and the needs of our customers make him the ideal leader to take Moody’s forward. He is uniquely suited to maximize Moody’s strengths and position the company for continued growth in the years ahead.”
Mr. Fauber, 50, was appointed COO in 2019 to drive strategic initiatives at the company. In that role, he has overseen both Moody’s Investors Service (MIS) and Moody’s Analytics (MA), as well as Strategy and Marketing for Moody’s Corporation (MCO). Mr. Fauber previously served as President of MIS, Head of the MIS Global Commercial Group and as Head of Corporate Development for MCO. He joined Moody’s in September 2005.
“Today’s announcement is the result of a thoughtful and deliberate planning process that will allow Rob to move seamlessly into his new role as CEO,” Dr. McKinnell said. “Over many years, the Board and I have come to know Rob as a strategic, innovative and results-oriented leader. He has made outstanding contributions to Moody’s, and the Board has complete confidence in his ability to lead the company to new heights.”
“On behalf of the entire Board, I want to thank Ray for his invaluable leadership over the course of his exceptional career,” Dr. McKinnell added. “With Ray as CEO, Moody’s has experienced the strongest growth in its history. Ray grew Moody’s core ratings and research business globally, expanded its international presence, built its data and analytics businesses, and introduced a number of new products and services. Ray has positioned Moody’s well for continued growth and success, and we look forward to continuing to work with him in his role as Chairman.”
Mr. McDaniel, 62, has served as Moody’s Chief Executive Officer since April 2005, first as Chairman and CEO and as President and CEO since April 2012. Since joining Moody’s as a Senior Analyst in 1987, Mr. McDaniel has held a series of senior positions at the company, including President of MIS and Chief Operating Officer of MCO. He was appointed to the Board in April 2003.
“I am extremely grateful to have found a home at Moody’s over the past three decades and to have worked with so many talented and dedicated colleagues along the way,” said Mr. McDaniel. “It has been a privilege to lead Moody’s as it has grown to serve even more customers globally and bring clarity to an increasingly complex, interconnected world.”
Mr. Fauber said, “It is an honor to have the opportunity to lead Moody’s and to build on Ray’s accomplishments. I thank Ray for his mentorship and support and look forward to working with the Board and the entire Moody’s team to provide trusted insights and standards to help decision-makers act with confidence.”
About Robert Fauber
Mr. Fauber has served as Moody’s Chief Operating Officer since 2019. He served as President of Moody’s Investors Service, Inc. from 2016 to 2019 and as Head of the MIS Global Commercial Group from 2013 to 2016. Mr. Fauber was Head of Corporate Development for Moody’s Corporation from 2005 to 2013. Prior to Moody’s, he served in several roles at Citigroup and its investment banking subsidiary Salomon Smith Barney.
About Raymond McDaniel, Jr.
Mr. McDaniel has served as Moody’s President and Chief Executive Officer since 2012 and served as Chairman and Chief Executive Officer from 2005 until 2012. Mr. McDaniel previously served in a variety of roles, including as Moody’s President, Chief Operating Officer, Head of Global Ratings and Research for MIS, and Managing Director, International. He is a director of John Wiley & Sons, Inc. and a member of the Board of Trustees of Muhlenberg College.
About Moody’s Corporation
Moody’s (NYSE:MCO) is a global risk assessment firm that empowers organizations to make better decisions. Its data, analytical solutions and insights help decision-makers identify opportunities and manage the risks of doing business with others. We believe that greater transparency, more informed decisions, and fair access to information open the door to shared progress. With over 11,200 employees in more than 40 countries, Moody’s combines international presence with local expertise and over a century of experience in financial markets. Learn more at moodys.com/about.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dixa, the Next-Gen CX Platform, Raises $105M Series C to Transform Customer Service Worldwide28.7.2021 15:30:00 EEST | Press release
Founded as a customer service solution that evolved into a customer engagement platform, European company Dixa today announced a Series C funding round totaling $105M. The company is leading the change from customer service to value creation with a multiexperience approach, challenging the status quo and delivering value-driven experiences that generate results for businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210728005430/en/ Dixa Founding Team (Photo: Business Wire) The Series C round is led by General Atlantic, a leading global growth equity investor with a history of backing and scaling companies that transformed their industries, with participation from existing investors Notion Capital Project A and Seed Capital. Dixa will leverage the new funds to invest in product development, including potential new acquisitions (following Dixa’s acquisition of Melbourne-based Elevio in January 2021), and plans to quadr
V.E, Part of Moody’s ESG Solutions, Provides Second Party Opinion on the Kingdom of Spain’s Sovereign Green Bond Framework28.7.2021 15:30:00 EEST | Press release
Moody’s ESG Solutions Group announced today that V.E has provided a Second Party Opinion (SPO) on the Kingdom of Spain’s Sovereign Green Bond Framework. The Framework is aligned with the four core components of the Green Bond Principles 2021 and follows best market practices identified by V.E. Net proceeds of the bonds will exclusively be used to finance or refinance projects tied to the country’s environmental objectives, including renewable energy, biodiversity protection, and climate change adaptation. “The bonds issued under Spain’s Framework will provide an ‘advanced’ contribution to sustainability, the highest score on our four-point scale,” said Patrick Mispagel, MD – Sustainable Finance at Moody’s ESG Solutions. “Our assessment reflects that in many cases Spain’s Framework followed the detailed technical eligibility criteria of the EU Taxonomy Climate Delegated Act. We expect to see additional sovereign issuances as nations increasingly seek to raise capital to support climate
U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda’s Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1)28.7.2021 15:15:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to TAK-994,1 its Phase 2 investigational oral orexin agonist, which is designed to selectively target orexin 2 receptors. TAK-994 is currently being studied for the treatment of excessive daytime sleepiness (EDS) in patients with narcolepsy type 1 (NT1),2 a chronic neurological disorder that alters the sleep-wake cycle.3 EDS is a hallmark symptom of NT1 and is characterized by a person’s inability to stay awake and alert throughout the day, and falling asleep unintentionally or at inappropriate times on a daily basis.3,4 The FDA’s Breakthrough Therapy Designation process is designed to expedite the development and review of a drug that is intended to treat a serious condition, for which preliminary clinical evidence exists indicating it may demonstrate a substantial improvement over available therapies on at
BlueConic is the First Customer Data Platform to Offer a Data Clean Room Solution28.7.2021 15:02:00 EEST | Press release
Driven by the death of the third-party cookie and its debilitating impact on the digital advertising industry, data clean rooms are growing in popularity among brands and publishers alike. To meet this demand, BlueConic is proud to announce its own comprehensive data clean room solution, making it the first customer data platform (CDP) to do so. The move will enable its customer base of over 300 companies worldwide to facilitate second-party data sharing in a privacy-safe environment. The solution provides brands and publishers with a privacy-compliant way to combat the effects of Apple and Google’s decisions to deprecate the use of third-party cookies in their respective web browsers, Safari and Chrome. Without such a solution, marketers will lose the ability to measure the impact of digital advertising spend once and for all. Industry analysts agree that BlueConic is uniquely poised to offer such a solution. Unlike other data clean rooms on the market, BlueConic’s solution will: Insu
Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis28.7.2021 15:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the company will initiate a Phase 3 development program for the new once-daily investigational triple combination of VX-121/tezacaftor/VX-561 (deutivacaftor) in the second half of 2021. The combination of VX-121/tezacaftor/VX-561 was first identified as having potential for increased efficacy based on its ability to drive higher levels of chloride transport compared to TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in human bronchial epithelial cells in vitro. The combination of VX-121/tezacaftor/VX-561 was evaluated in a Phase 2 study in people with cystic fibrosis (CF) ages 18 and older with one F508del mutation and one minimal function mutation (F/MF) and in people with CF ages 18 and older with two F508del mutations (F/F). The regimen was generally well-tolerated, and the study met the primary efficacy endpoint of absolute change from baseline in ppFEV1 and all secondary efficacy endpoints including abso
Discover the History of Pisco, the Spirit Drink That Was Born in Peru 400 Years Ago28.7.2021 14:00:00 EEST | Press release
Every lover of spirits should know about pisco. Therefore, it is not surprising that this distillate has achieved international notoriety and been included as a de rigueur item of the ultimate bucket list in “Captain America: Winter Soldier” in 2014. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210728005437/en/ (Photo: Business Wire) What many don't know is its origin and the fascinating journey it would make 200 years later: in 1553, the vines of the Canary Islands arrived in Peru with the strains that gave rise to pisco (Quechua word for “bird,” which is also the name of a Peruvian city founded in 1640 by viceroy Pedro Toledo y Leyva) and in 1779, navigator Francisco de la Bodega y Quadra took this drink from Pisco (Peru) to San Francisco for the first time, when both cities were still part of the Spanish empire. Thus, in 1850 the Pisco Punch was created, the flagship cocktail for the entire West Coast of the United Stat
FRISS Raises $65 Million Series B Funding Led by Accel-KKR28.7.2021 14:00:00 EEST | Press release
FRISS, the most widely adopted provider of AI-powered end-to-end fraud prevention and detection solutions for P&C insurers worldwide, today announced it closed a $65 million Series B funding round led by Accel-KKR, advised by FT Partners and endorsed by existing investor, Aquiline. The funding will fuel the company’s rapid growth with additional product innovations, deep market penetration and lines of business expansions. FRISS serves insurers in over forty countries today, and is well on track to deliver over $2 billion in fraud savings to insurers in 2021 alone. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210728005113/en/ FRISS Raises $65 Million Series B Funding Led By Accel-KKR (Graphic: Business Wire) Insurance fraud is a large and growing problem faced by insurance companies, with estimates of fraud in as much as 10-17% of total claims paid annually – a staggering $80 billion annual loss in the US insurance market
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom